ABSTRACT
Background Evidence-based infection control strategies are needed for healthcare workers (HCWs) following high-risk exposure to SARS-CoV-2. This study evaluated the negative predictive value (NPV) of a home-based 7-day infection control strategy.
Methods HCWs advised by their Infection Control or Occupational Health officer to self-isolate due to a high-risk SARS-CoV-2 exposure were enrolled between May-September 2020. The strategy consisted of symptom-triggered nasopharyngeal SARS-CoV-2 RNA testing from day 0-6 post exposure, followed by standardized home-based nasopharyngeal swab and saliva testing on day 7. The NPV of this strategy was calculated for i) clinical COVID-19 diagnosis from day 8-14 post exposure, and for ii) asymptomatic SARS-CoV-2 detected by standardized nasopharyngeal swab and saliva specimens collected at days 9-10 and 14 post exposure. Interim results are reported in the context of a second wave threatening this essential workforce.
Results Among 30 HCWs enrolled to date (age 31±9 years, 24 [80.0%] female), 3 were diagnosed with COVID-19 by day 14 post exposure (secondary attack rate 10.0%), with all cases detected by the 7-day infection control strategy: NPV for subsequent clinical COVID-19 or asymptomatic SARS-CoV-2 detection by day 14 was 100.0% (95%CI: 93.1-100.0%).
Interpretation Among HCWs with high-risk exposure to SARS-CoV-2, a home-based 7-day infection control strategy may have a high NPV for subsequent COVID-19 and asymptomatic SARS-CoV-2 detection. While ongoing data collection and data sharing are needed to improve the precision of the estimated NPV, we report interim results to inform infection control strategies in light of a second wave threatening this essential workforce.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the McGill Interdisciplinary Initiative in Infection and Immunity (Mi4) [grant number ECRF-R1-33].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MUHC REB (Research Ethics Board of the McGill University Health Center) Reviewing REB approval date2020-04-12 Date of final authorization2020-04-12
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding and support: The study was funded by the McGill Interdisciplinary Initiative in Infection and Immunity (MI4) Emergency COVID-19 Research Fund and the Rossy Foundation. Personal protective equipment was donated in-kind from AMD Medicom and Jor-Al Imports. Benjamin M Smith is supported by salary award from the Fonds de recherche santé du Québec (FRSQ). The funders had no role in the study design, execution, reporting or decision to publish the findings.
Declaration of Competing Interests: The authors report no competing interests related to the content of this manuscript.
Data Availability
The data that support the findings of this study are available from the corresponding author, Laura Rendon, upon request with appropriate ethics approvals.
